MarketPulse

pharmaceutical development

3 articles
The Motley FoolThe Motley Fool··Jonathan Ponciano

Viking Therapeutics Lands $7M Investment as Obesity Drug Pipeline Gains Momentum

ACT Capital Management invests $7.25M in Viking Therapeutics, backing its obesity treatment candidate VK2735 showing 14.7% weight reduction in Phase 2 trials.
CVXVKTXKRYSABVXPhase 3 trialsclinical-stage biotech
GlobeNewswire Inc.GlobeNewswire Inc.··Kdventures Ab

Organon Discontinues Second Forendos Drug Candidate, KDventures Faces Total Loss

Organon discontinues second Forendo drug candidate for PCOS, eliminating all programs from 2021 acquisition. KDventures writes off remaining contingent consideration entirely.
OGNpharmaceutical developmentdrug development discontinuation
BenzingaBenzinga··Vandana Singh

Teva Advances Monthly Schizophrenia Injection Toward FDA Approval

Teva's once-monthly schizophrenia injection TEV-749 advances toward FDA approval, aiming to improve patient medication compliance and reduce healthcare burden compared to daily oral treatments.
TEVAFDA approvalschizophrenia treatment